Results 261 to 270 of about 414,407 (362)

Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-κB/FGF21 signaling axis. [PDF]

Commun Biol
Li J, Zhou Z, Kong Y, Li Y, Wang Z, Yang Y, Wang J, Liu T, Wang X, Luo D, Zhang F, Qiu C, Liu J.   +12 more
europepmc   +1 more source

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Impact of glucocorticoid administration on therapeutic outcomes of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Zhang S, Chen SD, Chen L, Hong B.
europepmc   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

Early-stage cost-utility analysis of novel diagnostic tests for giant cell arteritis: a modelling study in UK secondary care. [PDF]

BMJ Open
Yang M, Cocco P, Mackie SL, Morgan AW.
europepmc   +1 more source

Integrative single cell RNA‐sequencing and spatial transcriptomics uncovers distinct macrophage‐fibroblast cross‐talk in human hip synovium between patients with femoroacetabular impingement and osteoarthritis

Arthritis &Rheumatology, Accepted Article.
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova, Alexis Klee, Mina Botros, Victoria L. Hansen, John Reuter, Eliya Tazreena Tashbib, Eloise Fadial, Benjamin F. Ricciardi, Brian Giordano, Chia‐Lung Wu   +9 more
wiley   +1 more source

Risk Factors for Osteoporotic Vertebral Compression Fracture and Evaluation of Clinical Outcomes of Minimally Invasive Vertebral Augmentation. [PDF]

Global Spine J
Zhu Z, Li Y, Chen J, Su S, Tao R, Wang D.   +5 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Efficacy and side effects of long-term treatment strategies of canine primary hypoadrenocorticism. [PDF]

Front Vet Sci
Dobosz DA, Zablotski Y, Wehner A.
europepmc   +1 more source